In addition to BACE1, our study utilizing multi-target drug modeling and surface plasmon resonance experiments identified Aβ 1-42 as a high-affinity target of berberine, suggesting its potential in treating Alzheimer’s disease (Chu et al., 2018). The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.